Immunoassay Market Size By Product, By Technology (ELISA, Chemiluminescence Immunoassay, Immunofluorescence Assay, Rapid Tests, ELISpot, Western Blotting), By Specimen, By Application, By End-User, By Geographic Scope And Forecast

Immunoassay Market Size And Forecast

Immunoassay Market size was valued at USD 27.53 Billion in 2023 and is projected to reach USD 39.66 Billion by 2031, growing at a CAGR of 4.67% from 2024 to 2031. An immunoassay is a laboratory technique that detects the presence or quantity of a material, usually a protein or other biomolecule, by analyzing its interaction with certain antibodies. To put it simply, antibodies are used to recognize and bind to the target molecule, allowing it to be identified or quantified. Immunoassays are widely used in a variety of disciplines, including medicine, biology, environmental science, and food safety. In medicine, they are commonly used to diagnose infectious diseases, monitor hormone levels, identify medications or poisons in the body, and test immunological responses to immunizations.

Additionally, they are used in agriculture to identify toxins in food, as well as in environmental monitoring to quantify pollutants in water and soil.

Global Immunoassay Market Dynamics

The key market dynamics that are shaping the immunoassay market include:

Key Market Drivers

Increased Prevalence of Chronic Diseases:

The increased global incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders needs early detection and monitoring, is driving the demand for immunoassays in clinical settings for accurate and speedy testing.

Advancements in Technology:

Continuous developments in immunoassay technology, including automation and high-throughput systems, have improved the tests' efficiency, sensitivity and specificity. This technological advancement enables improved illness identification and monitoring, bolstering the expansion of immunoassay market.

Growing Demand for Point-of-Care Testing:

The demand for quick, dependable, and simple diagnostic tests at point-of-care locations (such as clinics and home care) is growing. Immunoassays with quick findings are becoming vital tools in these settings, growing the market.

Expansion of Applications in Drug Development and Therapeutics:

Immunoassays are increasingly used in drug development and therapeutics, where they aid in drug discovery, pharmacokinetics, and toxicology research. The increasing investment in research and development activities in these industries drives up demand for immunoassays, accelerating market expansion.

Key Challenges:

High Cost of Advanced Immunoassay Systems:

The development and application of sophisticated immunoassay technologies are costly. This includes the cost of expensive equipment and reagents, which is a substantial impediment to smaller laboratories and healthcare organizations adopting these technologies, limiting market expansion.

Lack of Skilled Professionals:

Advanced immunoassay findings have to be operated on and interpreted by highly competent individuals. There is a dearth of educated workers, which inhibits the effective usage and acceptance of immunoassay technology, particularly in emerging regions, preventing market expansion.

Key Trends:

Integration of Artificial Intelligence (AI) and Machine Learning (ML):

Artificial intelligence and machine learning are rapidly being integrated into immunoassay platforms to improve data processing and interpretation. This integration enhances diagnosis accuracy, allows for predictive analytics, and streamlines laboratory procedures, extending the limitations of standard immunoassay applications.

Point-of-Care (POC) and Home-Based Testing:

There is a rising trend towards designing compact, user-friendly immunoassay tests for point-of-care and home use. This transition is being driven by the demand for quick, convenient testing choices that yield instant findings, decreasing the need for specialized laboratory facilities.

Multiplex Assays:

Multiplexing, which allows for the simultaneous testing of numerous analytes, is becoming increasingly popular. This trend is gaining popularity owing to high demand for high-throughput, efficient testing procedures that save time and costs while giving comprehensive diagnostic information from a single sample.

Expansion into Emerging Markets:

The immunoassay market is growing in emerging economies, driven by rising healthcare spending, increased awareness of early disease diagnosis, and the creation of healthcare infrastructure. Despite constraints such as cost sensitivity and regulatory hurdles, this expansion opens up new prospects for immunoassay suppliers.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Immunoassay Market Regional Analysis

Here is a more detailed regional analysis of the Immunoassay Market:

North America:

According to Verified Market Research, North America is estimated to dominate during the forecast period. North America, particularly the United States, has an advanced healthcare infrastructure with extensive access to cutting-edge medical technologies. This allows for rapid adoption and integration of immunoassays across a variety of healthcare settings, resulting in market growth.

The region has one of the world's highest healthcare expenditures, with major investments in R&D. This financial capability encourages the use of pricey immunoassay technology in diagnostics and research, hence boosting the market.

Many of the world's leading immunoassay and biotechnology companies are based in North America. These organizations are at the cutting edge of innovation, contributing to the region's market domination through ongoing product development and strategic alliances.

Furthermore, the increased prevalence of chronic diseases in North America needs early detection and monitoring, including cancer, diabetes, and cardiovascular disease. This has resulted in increased demand for immunoassay-based diagnostics, which is driving market expansion in this region.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Many Asia Pacific countries are making considerable investments in healthcare infrastructure, such as hospitals and research institutions. This growth enables the use of modern diagnostic technologies, such as immunoassays, to cater to a rising patient base.

This region's economies are growing, thereby, contributing to a rise in healthcare spending. Governments and the corporate sector are increasing their investments in healthcare, especially preventative care and diagnostics, driving up demand for immunoassay technologies.

The public in the Asia Pacific region is becoming more aware of the necessity of early disease identification and frequent health checkups. This trend is resulting in greater use of immunoassays for screening and monitoring a variety of disorders.

Furthermore, chronic disease prevalence is increasing in the Asia Pacific region, with diabetes, cancer, and cardiovascular disease being among the most common. This public health concern emphasizes the importance of efficient and accurate diagnostic tests, such as immunoassays, for effectively managing and controlling these illnesses.

Europe:

Europe's population is ageing, making it increasingly prone to chronic diseases that require regular monitoring and diagnostic tests. As a result, there is a growing demand for immunoassays to identify cardiovascular illnesses, cancer, and autoimmune disorders.

Most European countries have high healthcare standards, with significant public and private investment in healthcare systems. This funding commitment promotes the use of modern diagnostic technologies, such as immunoassays, throughout the region.

Furthermore, Europe is home to some of the world's best research institutes and biotechnology businesses, generating a robust R&D ecosystem. This strong scientific community drives constant innovation in immunoassay technology and the creation of new assays, both of which contribute to market growth.

Global Immunoassay Market Segmentation Analysis

The Immunoassay Market is segmented based on Product, Technology, Specimen, Application, End-User, And Geography.

Immunoassay Market, By Product

• Reagents & Kits
• ELISA Reagents & Kits
• CLIA Reagents & Kits
• IFA Reagents & Kits
• Rapid Test Reagent & Kits
• ELISpot Reagent & Kits
• Western Blot Reagent & Kits
• Other Reagents & Kits
• Analyzers
• Open Ended Systems
• Closed Ended Systems

Based on Product, the market is segmented into Reagents & Kits and Analyzers. The reagents & kits segment is estimated to dominate the immunoassay market due to their broad use in a range of applications, including clinical diagnostics, research, and drug development. Reagents and kits are required for the execution of immunoassays and are used in greater numbers than analyzers, which are capital equipment with longer replacement cycles. The need for reagents and kits stems from the necessity for regular replenishment, the development of new tests, and the expansion of immunoassay applications in both healthcare and research contexts.

Immunoassay Market, By Technology

• ELISA
• Chemiluminescence Immunoassay (CLIA)
• Immunofluorescence Assay (IFA)
• Rapid Tests
• ELISpot
• Western Blotting
• Other Technologies

Based on Technology, the immunoassay market is segmented into ELISA, CLIA, IFA, Rapid Tests, ELISpot, Western Blotting and Others. The ELISA segment is estimated to exhibit the highest growth in the market over the forecast period owing to its broad use in clinical and scientific contexts due to its specificity, sensitivity, and adaptability. This technique is well-known and has been well-validated for a variety of applications, including illness diagnosis, vaccine development, and quality control operations. Furthermore, ELISA kits are available for a wide range of targets, making them the preferred method for detecting and measuring proteins, hormones, antibodies, and antigens.

Immunoassay Market, By Specimen

• Blood
• Saliva
• Urine
• Other Specimens

Based on Specimen, the market is segmented into Blood, Saliva, Urine and Other Specimens. The blood specimen segment is estimated to lead this segment during the forecast period. This dominance is attributed to blood tests' rich diagnostic information, which makes them the preferred option for a wide range of disorders and conditions. Blood-based immunoassays are essential for detecting viral diseases, hormone imbalances, drug monitoring, and biomarkers for a variety of chronic and acute illnesses. Blood tests are widely used in clinical diagnostics due to their reliability, accuracy, and broad applicability, as well as standardized collection and processing techniques.

Immunoassay Market, By Application

• Infectious Diseases
• Endocrinology
• Oncology
• Bone & Mineral Disorders
• Cardiology
• Blood Screening
• Autoimmune Disorders
• Allergy Diagnostics
• Toxicology
• Newborn Screening
• Other Applications

Based on Application, the market is segmented into Infectious Diseases, Endocrinology, Oncology, Bone & Mineral Disorders, Cardiology, Blood Screening, Autoimmune Disorders, Allergy Diagnostics, Toxicology, Newborn Screening and Other Applications. Infectious Disease is estimated to hold the majority share in the immunoassay market owing to the high global prevalence of infectious diseases such as HIV, TB, and hepatitis, as well as the increasing occurrence of new and emerging infections. The COVID-19 pandemic emphasized the importance of immunoassays in detecting infectious agents quickly and accurately, resulting in a considerable increase in demand for these tests.

Immunoassay Market, By End-User

• Hospitals & Clinics
• Clinical Laboratories
• Pharmaceutical & Biotechnology
• Blood Banks
• Research & Academic Laboratories
• Home Care Settings

Based on End-User, the market is segmented into Hospitals & Clinics, Clinical Laboratories, Pharmaceutical & Biotechnology, Blood Banks, Research & Academic Laboratories and Home Care Settings. The hospitals & clinics segment is estimated to show the highest growth in the forecasted period due to a wide range of services such as diagnostic testing, patient care, and illness treatment. Hospitals and clinics provide primary healthcare to the great majority of the population, allowing for disease detection, diagnosis, and treatment at an early stage. The large patient volume in these settings raises the demand for immunoassay tests, making them an essential component of patient care practices.

Immunoassay Market, By Geography

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Based on Geography, the immunoassay market is classified into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. North American region is estimated to hold the largest share in the immunoassay market. North America, particularly the United States, has a highly developed healthcare system that allows for the rapid adoption and integration of new diagnostic technology, such as immunoassays. The region's significant investment in healthcare and R&D promotes innovation and the development of novel immunoassay techniques and platforms.

Key Players

• The "Immunoassay Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Abbott Laboratories, Danaher Corporation, Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Johnson & Johnson, Meriden Life Sciences, Trinity Biotech plc, Mindray Medical International Limited, DiaSorin S.p.A., Hycel Ltd., Euroimmun AG, Stago Diagnostica, and Arkray.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Immunoassay Market Recent Developments
• In February 2024, Abbott announced the FDA has approved the ARCHITECT Sepsis hTHP, a revolutionary AI-powered immunoassay that employs machine learning to detect sepsis faster and more precisely. This development has the potential to greatly enhance patient outcomes in this life-threatening illness.
• In February 2024, Roche launched the Elecsys tau blood test, an immunoassay intended to aid in the early identification of Alzheimer's disease. This advancement shows hope for earlier intervention and better patient care in this progressive neurodegenerative disease.
• In February 2024, Quidel collaborated with Merck to create and commercialize point-of-care immunoassays for infectious illnesses. This collaboration intends to provide faster and more accessible diagnostic options to patients in a variety of healthcare settings.